Summary - VRTX - NASDAQ - Weiss Ratings

C

Vertex Pharmaceuticals Incorporated VRTX

$440.66 $2.010.46% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$377.85 - $519.88

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Biotechnology Health Care Pharmaceutical

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Best Biotech Stocks to Buy in 2025

5/13/2025 - MarketBeat

Vertex Pharmaceuticals (VRTX) Announces New $4 Billion Stock Repurchase Program

5/19/2025 - GuruFocus

Top Biotech Stocks To Watch Today - May 18th

5/19/2025 - MarketBeat

August 15th Options Now Available For Vertex Pharmaceuticals (VRTX)

5/19/2025 - Stock Options Channel

Notable ETF Inflow Detected - QLD, ADBE, AMGN, VRTX

5/19/2025 - ETF Channel

Westport Asset Management Inc. Acquires New Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/19/2025 - Ticker Report

VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss

5/19/2025 - StockStory Articles

Royal Bank of Canada Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/19/2025 - MarketBeat

Promising Biotech Stocks To Follow Today - May 17th

5/18/2025 - MarketBeat

Prediction: This Beaten-Down Stock Could Double in The Next 5 Years

5/18/2025 - Fool.com Headlines

Quantinno Capital Management LP Has $9.70 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/18/2025 - MarketBeat

Biotech Stocks To Follow Today - May 16th

5/17/2025 - MarketBeat

Royal Bank of Canada Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/17/2025 - Ticker Report

Polar Asset Management Partners Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/17/2025 - MarketBeat

Pathstone Holdings LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/17/2025 - MarketBeat

Nuveen Asset Management LLC Buys 261,891 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/17/2025 - MarketBeat

Top Biotech Stocks Worth Watching - May 15th

5/16/2025 - MarketBeat

3,802 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Mufg Securities Americas Inc.

5/16/2025 - MarketBeat

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Nia Impact Advisors LLC

5/16/2025 - MarketBeat

Nissay Asset Management Corp Japan ADV Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/16/2025 - MarketBeat

1 Large-Cap Stock to Target This Week and 2 to Question

5/16/2025 - StockStory Articles

Vertex to Participate in Upcoming Investor Conferences

5/15/2025 - Business Wire

Biotech Stocks Worth Watching - May 14th

5/15/2025 - MarketBeat

Polar Asset Management Partners Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

5/15/2025 - Ticker Report

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

1/23/2025 - MarketBeat

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Tuesday, May 6, 2025

Period Date

Monday, March 31, 2025

Next Filing

Beginning of August (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Dec 19, 2024 - $377.85

52-week High

Nov 08, 2024 - $519.88

Valuation

Market Cap

$112.64B - Large Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

Phone Number

617 341 6100

Address

50 Northern Avenue
Boston, MA 02210

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF... more